Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ambys Medicines, a US-based regenerative medicine developer focused on serious liver diseases, may not be a typical spinout but it is the latest company emerging from venture capital firm Third Rock Ventures’ unique “discover, launch, build” model.
The approach has the firm collaborate with researchers to identify high-potential projects before helping them launch their company with significant series A funding and assisting their growth in the marketplace through a network of pharmaceutical partners.
Third Rock will be familiar to Global University Venturing readers – its portfolio includes companies such as Celsius Therapeutics, a developer of treatments for cancer and autoimmune diseases, cancer therapy developer Relay Therapeutics and cancer-focused biopharmaceutical company Constellation Pharmaceuticals.
Ambys Medicines is the latest addition, having been launched last week with $140m in total financing, made up of $60m in series A capital provided by Third Rock and pharmaceutical company Takeda, with an additional $80m…
